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9550 | RSC Adv., 2021, 11, 9550–955elf-associating amphiphiles (SSAs)
as enhancers of antimicrobial agents towards
Escherichia coli (E. coli)†
Jessica E. Boles, Rebecca J. Ellaby, Helena J. Shepherd and Jennifer R. Hiscock *
Supramolecular self-associating amphiphiles (SSAs) are a class of amphiphilic salt which have demonstrated
antimicrobial activity against both Gram-positive and Gram-negative bacteria. Herein, we show that SSAs
are also able to increase the efficacy of a range of currently used antimicrobial/therapeutic agents with
a range of different chemical structures and modes of antimicrobial action against Gram-negative
Escherichia coli, which include: octenidine (an antiseptic); ampicillin (an antibiotic); and cisplatin (a DNA
chelating agent). Additionally, we show these effects to be dependent on the order of agent addition.
Finally, through completion of a range of 1 : 1 SSA : antimicrobial/therapeutic agent physicochemical
studies we gain an understanding as to how the self-association events and resultant SSA aggregate
structure are effected by the presence of these secondary molecular species.Introduction
The discovery of antibiotics/antimicrobials has revolutionised
healthcare, with these agents becoming a game changing
weapon in the ght against bacterial infections.1 However, since
the rst legitimate use of these agents, bacteria have evolved
resistance. The ongoing misuse of these same compounds
within the clinical,2 veterinary3 and animal feedstuff sectors,4
has resulted in the development of widespread microbial
resistance and the emergence of multi-drug-resistant bacterial
strains.5 To date, antimicrobial resistance (AMR) has now been
reported towards all antimicrobial agents currently available,6
including antiseptics such as octenidine6 and more ominously,
the antibiotic of last resort, colistin.7 Additionally, a recently
commissioned UK governmental report has predicted that by
2050, approximately 10 million people per year will die globally
from the primary effects of AMR, overtaking those caused by
cancer in 2014, ca. 8.2 million per year.8
In light of the growing prevalence of AMR, the development
of new molecular weapons to combat the threat of bacterial
infection are of increasing importance.5 The development of
such technologies include those driven by the supramolecular
chemistry community.9 Developments in this area include work
by Gunnlaugsson et al. who have used the aryl-pyridyl ureat, Canterbury, CT2 7NH, UK. E-mail: J.R.
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6
scaffold within supramolecular gelator design to produce
a material which demonstrates antimicrobial activity against
both Gram-positive methicillin resistant Staphylococcus aureus
(MRSA) and Gram-negative Escherichia coli (E. coli).10 In addi-
tion, Hou et al. have demonstrated the ability of pillar[5]arenes
to selectively insert into Gram-positive bacterial membranes,
exhibiting efficient antimicrobial activity against Staphylococcus
epidermidis.11 Furthermore, the supramolecular silica nano-
platform developed by Zink et al. has been shown to co-deliver
the antibiotic ooxacin and the antimicrobial peptide melittin
for synergistic eradication of Pseudomonas aeruginosa PAO1
biolms.12 Finally, Zhang et al. have demonstrated the
enhanced antibacterial activity of silver nitrate when combined
with PEGylated bisimidazolylbenzyl alcohol, against both MRSA
and E. coli.13
Our own work in this area has focused on the development of
a novel class of supramolecular, self-associating amphiphilic
salts (SSAs), such as those exemplied by 1 (Fig. 1).14–21 Similar
constructs developed by Faustino and co-workers have previ-
ously been shown to act as amphiphiles with enhanced
surfactant properties, attributed to intermolecular hydrogen
bonded self-association.22,23 Additionally, Supuran et al. have
shown the promise of agents such as SSAs for development as
therapeutics against Mycobacterium tuberculosis (TB).24 To date,
members from this >70 compound SSA library have been shown
to self-associate within the solution state, producing self-
associated dimers, spherical aggregates and hydrogels.16 Addi-
tionally, SSAs have also demonstrated antimicrobial activity
against Gram-positive MRSA and Gram-negative E. coli.14–16,20
This previous work has led us to hypothesise that SSA antimi-
crobial activity is linked to both molecular self-association and
selective SSA:phospholipid complexation, resulting in© 2021 The Author(s). Published by the Royal Society of Chemistry
Fig. 1 Chemical structures of SSA 1 and antimicrobial/therapeutic co-
formulants 2–6. TBA ¼ tetrabutylammonium. The NHs highlighted in
green, blue and orange indicate the resonances monitored during 1H
NMR dilution studies (Fig. 3).
Fig. 2 A single crystal X-ray structure obtained from a single crystal
sample produced from a solution of co-formulation a in acetone. Grey
¼ carbon, blue ¼ nitrogen, red ¼ oxygen, yellow ¼ sulfur, white ¼
























































































View Article Onlinemolecular membrane permeation events.15,16,25,26 Additionally,
not only have we shown SSAs to arrive at the external microbial
membrane as self-associated spherical aggregates,16 but that
these aggregates can incorporate small drug(like) guest
species.17 The summation of this evidence has therefore led us
to hypothesise that this class of compound has the potential to
act as efficacy enhancers for other therapeutic agents. Herein,
we characterise the SSA aggregates formed upon the co-
formulation of 1 (Fig. 1) with examples of antiseptics, antibi-
otics, and other antimicrobial/cytotoxic agents (2–6). Addition-
ally, we explore the ability of 1 to enhance the activity of 2–6
against the model Gram-negative bacteria, E. coli.Results and discussion
Physicochemical characterisation of SSA co-formulations
A series of SSA co-formulation physicochemical studies, con-
ducted in line with previous work,17 allowed us to understand
the effects of the addition of 2–6 on the self-associative prop-
erties of SSA 1, when supplied in an 1 : 1 molecular ratio. The
preparation of these 1 : 1 SSA : secondary compound mixtures
produced co-formulations a–e, as detailed in Table 1. Here, 1










a 1 + 2 d 1 + 5
b 1 + 3 e 1 + 6
c 1 + 4
© 2021 The Author(s). Published by the Royal Society of Chemistrywhereas 2–6were purchased from commercial sources and used
without further purication.
Due to the complexities associated with SSA self-association
events, the physicochemical properties of 1 when co-formulated
with 2–6 have been studied through a variety of complimentary
methods that include: single crystal X-ray diffraction, quanti-
tative 1H NMR, 1H NMR self-association constant determina-
tion, 1H NMR DOSY, dynamic light scattering (DLS), zeta
potential studies, surface tension and critical micelle concen-
tration (CMC) determination.†However, we have not attempted
scanning/transmission electron microscopy (SEM/TEM)
studies, as the self-associated aggregate structures produced
by SSAs have previously been shown not to survive traditional
SEM/TEM sample preparation methods.27
Slow evaporation of co-formulation a in acetone led to the
generation of a crystal sample, suitable for single crystal X-ray
diffraction analysis, Fig. 2.‡ Here 2 has undergone a reaction
with the acetone, as previously described by Sarcevica et al.28
The product of this reaction, the cation shown in Fig. 2, has
then formed a salt with the anionic component of 1. Here we see
the formation of a hydrogen bonded urea-sulfonate anionic
tape, similar to that observed previously for the pyridinium salt
of this same anion.29 As observed for this analogous structure,
the counter cation is also involved in competitive hydrogen
bonded complexation events with the anionic sulfonate group,
preventing sulfonate-urea dimer formation as observed for 1
only.29
SSA self-association events are known to be dependent on
solvent environment, typically forming hydrogen bonded
anionic dimers in DMSO, larger (z100–550 nm in diameter)
self-associated spherical aggregates in aqueous or aqueous
ethanol (19 : 1 H2O : EtOH) solutions and self-associated
hydrogel bers in aqueous salt solutions.16 Initially, to enable‡ A suitable crystal was selected and mounted on a Rigaku Oxford Diffraction
Supernova diffractometer. Data were collected using Cu Ka radiation at 100 K.
The structure was solved with the ShelXS38 via direct methods and rened with
ShelXL39 on least squares minimisation. Olex2 (ref. 40) was used as an interface
to all ShelX programs. CCDC deposition number for the structure shown in
Fig. 2 ¼ 1999018.
RSC Adv., 2021, 11, 9550–9556 | 9551
Table 3 Hydrodynamic diameter (DH) (nm) of thosemolecular species
present in a DMSO-d6/0.5% H2O solution at 298 K, as determined by
1H NMR DOSY. Self-association dimerization constants (Kdim) (M
1)
calculated for 1 and co-formulations a–e in a DMSO-d6/0.5% H2O
solution at 298 K. These constants were obtained from the fitting of 1H
NMR dilution data and refined to the EK/dimerization model using






errorSSA anion SSA cation Co-formulant
1 only19 1.15 1.08 n/a 2.7 0.3
a 1.23 1.13 0.74 2.09 1. 5
b 1.57 1.51 1.37 4.37 0.3
c 1.69 1.74 2.21 2.92 0.8
d 1.70 1.29 1.99 4.91 0.5
e a a a 3.67 0.4
a a ¼ values could not be determined due to peak overlap. n/a ¼ not
applicable.
Table 2 Overview of the results from quantitative 1H NMR studies
obtained from (i) DMSO-d6, standardised with 1.0% DCM at 112 mM
and; (ii) D2O standardised with 5.0% ethanol at 5.56 mM. Values given
in % represent the observed proportion of compound to become NMR
silent. All quantitative 1H NMR experiments were conducted with
a delay time (d1) of 60 s at 298 K. Control ¼ compound 1 only
Co-formulation Solvent system Anion Cation Co-formulant
1 only19 DMSO-d6 0 0 n/a
D2O 51 50 n/a
aa DMSO-d6 0 0 0
D2O 56 57 50
ba DMSO-d6 0 0 0
D2O 50 49 41
ca DMSO-d6 0 0 0
D2O 53 29 64
da DMSO-d6 0 0 0
D2O 48 55 62
e DMSO-d6 0 0 0
D2O 65 83
b
a Analogous quantitative 1H NMR control experiments conducted with
2–5 only in a D2O solution standardised with 5.0% ethanol at
5.56 mM conrmed the absence of any larger self-associated
























































































View Article Onlinecharacterisation of those SSA self-associated species present
within the solution state, quantitative 1H NMR techniques are
used to conrm the presence of larger self-associated species.
Here comparative integration against an internal standard is
used to calculate the proportion of a molecular component
visible using standard solution state NMR techniques. The
proportion of a molecular component that appears ‘lost’ from
a solution is assumed to form larger higher-order self-
associated structures with solid-like properties, thus
rendering them NMR inactive. These studies are thus also able
to enable the elucidation of the proportion of any secondary
molecular substituents (such as 2–6) involved in the construc-
tion of these larger higher order species.
Those solutions which exhibit no apparent ‘loss’ of molec-
ular components, through comparative integration with the
appropriate internal standard, are taken forward for 1H NMR
self-association constant determination studies. These studies
enable us to quantify the strength of the hydrogen-bonded self-
association events undertaken by the anionic SSA components,
through completion of 1H NMR dilution studies and the
subsequent tting of these data and generation of self-
association constants, using BindFit v0.5.30 The limitation of
this method however, is that these models are limited to tting
one component, one dimensional, homogeneous aggregation
events.31
A summary of the quantitative 1H NMR results obtained for 1
alone and when co-formulated as co-formulations a–e in
a DMSO-d6 (1% DCM) and D2O (5% EtOH) solution at 112 mM
and 5.56 mM respectively is given in Table 2. As with SSA 1
alone, co-formulations a–e showed no evidence for the forma-
tion of larger self-associated species with solid-like properties in
a DMSO-d6 (1% DCM) solution.9552 | RSC Adv., 2021, 11, 9550–9556A complimentary series of 1H NMR DOSY studies conrmed
that under these experimental conditions, the anionic and
cationic components of the SSA and appropriate co-formulant
2–6, were all shown to exhibit different diffusion rates in
a DMSO-d6/0.5% H2O solution, meaning that these molecular
components are not strongly associated to one another. The
hydrodynamic diameter (DH) of the molecular species present
within these solutions, calculated using the Stokes–Einstein
equation from the appropriate diffusion rate measurements,
are listed in Table 3. The size of the species present also indi-
cates that as previously observed for this class of compound,
where self-association of the SSA's anionic component (1) exists,
it is likely to adopt a dimeric binding mode.
To verify the presence of any hydrogen bonded self-
association events within a DMSO-d6/0.5% H2O solution at
298 K, 1H NMR dilution studies were performed. From these
data collected, the change in chemical shi for those NH
resonances within the SSA anion and co-formulant were plotted
with respect to concentration (Fig. 3). With these data tted to
the dimerization (EK) model using Bindt v0.5,30 a Kdim of 2.7
M1 was calculated for 1 only.19 A similar Kdim of 2.1 M
1 was
calculated for the SSA anion in co-formulation a. This is not
surprising as comparing the change in chemical shi for those
NH resonances of the SSA anion and co-formulant 2, we
observed a downeld change in chemical shi for the urea NH's
of the anion but no discernible change for those NH resonances
associated with 2, meaning that it is unlikely this co-formulant
is involved within the SSA anion self-association events (Fig. 3a).
Fitting the analogous 1H NMR dilution data obtained for the
SSA component of co-formulations b and e to the same
dimerization isotherm resulted in an increased Kdim of 4.4 and
3.7 M1 respectively. Unfortunately, in this instance we were
unable to observe the position of the NH resonances associated
with co-formulants 3 and 6. Compound 6 is a metal complex
also capable of competing with any SSA self-association events.
However, 3 exists as an HCl salt, therefore introducing Cl ions
into the solution. It is likely that these ions will also compete© 2021 The Author(s). Published by the Royal Society of Chemistry
Fig. 3 Graphs illustrating the 1H NMR down-field change in chemical
shift of SSA (1) urea and appropriate co-formulant NH resonances in
DMSO-d6/0.5% H2O (298 K) for: (a) co-formulation a; (b) co-formu-
lation c; and (c) co-formulation d. The relevant NH's plotted within

























































































View Article Onlinewith the SSA sulfonate unit to coordinate with the urea func-
tionality and therefore, this complex self-associative event
would mean that these data are no longer appropriate to t to
this binding model, so this dimerization value should be
treated with caution.
When comparing the change in chemical shi values for the
different components of co-formulation c, the NH resonances of
the SSA anion and co-formulant (4) were found to exhibit
similar changes in chemical shi with respect to concentration
(Fig. 3b). This leads us to believe that co-formulant 4, is also
involved in molecular association/self-association events within
this solution. This means that once again the Kdim reported in© 2021 The Author(s). Published by the Royal Society of ChemistryTable 2 should be treated with caution due to the possible
complex nature of these self-association events. It is also
hypothesised that complex self-association events also occur
with co-formulation d (Fig. 3c). Here the co-formulant contains
a carboxylate functionality, carboxylate anions are known to
form stronger complexes with a urea functionality than the
sulfonate anion,32 therefore it is possible that this ion is pref-
erentially coordinating with the anionic component of the SSA.
Although the Kdim calculated in this instance is similar to that of
1 alone.
Moving from a DMSO-d6 solution into an aqueous D2-
O : EtOH 19 : 1 solution at an SSA/co-formulation concentration
of 5.56 mM at 298 K, our quantitative 1H NMR control experi-
ment (Table 2) containing 1 only shows 50% of this SSA to
become incorporated into larger self-associated structures. The
proportion of SSA (1) to become incorporated when supplied as
co-formulation b, remains the same as with the SSA only
however, 41% of 3 also becomes NMR silent. We hypothesise
that this is because this proportion of 3 is now incorporated into
the larger self-associated aggregates of 1. Interestingly, the
presence of 2 (co-formulation a) results in approximately 5–7%
more of the SSA becoming incorporated into these larger self-
associated aggregates, along with 50% of the available co-
formulant. We hypothesise that this may be due to the lack of
competitive Cl and H+ ions, alongside the stabilising effects of
uncharged, comparatively hydrophobic isoniazid (2) incorpo-
ration within the extended aggregate structure.
The cationic component of 4 in co-formulation c is amphi-
philic in nature and in the presence of this SSA (1) 64% of this
amphiphilic cation is incorporated into these larger SSA struc-
tures, replacing a portion of the SSA cation, as now 53% of the
SSA anion remains incorporated into the extended aggregate
structure whereas, only 29% of the SSA TBA counter cation is
now utilised within aggregate formation. The reverse is true for
co-formulation d. Here the carboxylate anion is incorporated
into the SSA self-associated aggregate (62%), replacing
a proportion of the SSA's anionic component (48%) in
comparison to the SSA counter cation (55%). Interestingly,
except for co-formulations a and e, the proportion of SSA anion
to be incorporated into those self-associated aggregate species
appears to be maintained at z50%.
To further characterise the formation of these larger self-
associated aggregates, CMC values were also determined for
co-formulations a–e and, compared to a control solution con-
taining 1 only. These results have been summarised in Table 4.
Here, co-formulation b exhibits a similar CMC value (11.21 mM)
to that of 1 only (10.39 mM) however, co-formulations a, c and e,
did exhibit decreased CMC values of 6.76 mM, 5.58 mM and
3.29 mM respectively. We hypothesise that this may be due to
the presence of the amphiphilic/comparatively non-polar
agents within these co-formulations. Interestingly the CMC
obtained for co-formulation d was found to have increased
signicantly from that of 1 only, from 10.38 mM to 16.24 mM. It
is believed that this is due to the presence of the carboxylate
moiety within the structure of 5. As suggested by the results of
the 1H NMR dilution studies, this compound perturbs the self-
associative interaction of the SSA anion. Here we predict thatRSC Adv., 2021, 11, 9550–9556 | 9553
Table 4 Overview of average DLS intensity particle size distribution peak maxima (aggregate DH measurements), zeta potential and CMC,
measurements obtained for a H2O/5.0% EtOH solution of an SSA (1) or co-formulation a–e (5.56 mM) at 298 K
a
Co-formulation DH (nm) Polydispersity (%)
Zeta potential
(mV) CMC (mM)
1 alone19 164 24 (1.20) 76 10.39
1* alone19 142 25 (0.68) 66 n/a
a 200 20 (1.56) 72 6.76
b 209 17 (1.65) 22 11.21
c* 240 25 (0.75) +76 5.58
d 136 13 (1.26) 3 16.24
e* 160 21 (21.51) 42 3.29
























































































View Article Onlinethose same competitive association events are responsible for
this increase in CMC. It is therefore plausible that the slight
increase in CMC observed for co-formulation bmay also be due
to competitive molecular association events. This hypothesis is
further supported by the results of comparative dynamic light
scatting and zeta potential studies (Table 4). Here a value of
76 mV was recorded for the control solution of 1 only at
5.56mM. This value was found to decrease through the addition
of 3 and 5 to 22 mV and 3 mV for co-formulations b and
d respectively while, the stability of those larger aggregate
structures formed with co-formulation a were found to exhibit
a similar stability to 1 alone.
To explore the effects of the presence of an SSA on the effi-
cacy of different currently available antimicrobial/therapeutic
agents with different modes of action, E. coli was chosen as
a model Gram-negative organism. Additionally, the effects ofFig. 4 Bar chart showing the increase/decrease in efficacy of the
antimicrobial/therapeutic agent (2–6) when supplied as a co-therapy
in the presence of SSA 1. These results have been normalised against
the combined bacterial growth inhibition effects of 1 and co-for-
mulants 2–6 alone. OD600 measurements were obtained at 1100
minutes against E. coli DH10B in the presence of SSA 1 (1.5 mM) and
either isoniazid (2) (1.45 mM), isoniazid hydrogen chloride (3) (1.73 mM),
octenidine dihydrochloride (4) (0.29 mM), ampicillin sodium salt (5)
(0.89 mM) or cisplatin (6) (16.6 mM). Each co-formulated system was
studied where the: (i) SSA was pre-incubated with the E. coli for 10 min
before the antimicrobial agent was added (green); (ii) antimicrobial
agent was pre-incubated with the E. coli for 10min before the SSA was
added (orange); (iii) SSA and antimicrobial agent was added in co-
formulation without any prior incubation (blue). The concentration of
2–6 alone was found to impede bacterial growth by <30% over
1100 min.
9554 | RSC Adv., 2021, 11, 9550–9556the order of SSA or antimicrobial/therapeutic agent addition
was also investigated. Here either the SSA and antimicrobial
agent was added simultaneously as the co-formulation (a–e) or,
the cells were incubated rstly; with the SSA only for 10
minutes, followed by the addition of the antimicrobial agent
and secondly; by incubating rst with the antimicrobial agent
for 10 minutes followed by the addition of the SSA. In this
instance the concentrations of both the SSA (1) and antimicro-
bial agents (2–6) were chosen through completion of microbial
susceptibility studies. These studies were conducted to ensure
that both the SSA and antimicrobial/therapeutic agent were at
a concentration where some inhibition of bacterial growth, and
therefore antimicrobial efficacy was being imparted on the E.
coli.† The results of these studies have been summarised for
convenience within Fig. 4.
The antimicrobial/therapeutic agents were chosen for this
study not only to be diverse in chemical structure but also
diverse in antimicrobial mode of action. These agents include:
(i) the antibiotic ampicillin (5) which inhibits the synthesis of
the peptidoglycan bacterial cell wall;33 (ii) octenidine (4) which
acts to disrupt the cell membrane,34 and is thought to therefore
act in a similar fashion to the SSAs themselves, at least in part;
(iii) cisplatin (6), which is more commonly considered an anti-
cancer agent, but still promotes bacterial cell death through
DNA cross-linking within the cell, preventing/blocking DNA
replication;35 (iv) two variations of isoniazid (2 and 3), which is
traditionally used to treat mycobacteria infections through
inhibition of mycolic acid synthesis.36
From these studies we have shown that when E. coli
undergoes combination therapy with both an antimicrobial
agent and an SSA, the presence of the SSA is able to enhance the
activity of the antimicrobial agent in the cases of octenidine (4),
ampicillin (5) and cisplatin (6). However, interestingly the
degree of antimicrobial efficacy enhancement was found to be
dependent on the order in which those agents were supplied as
part of the appropriate combination therapy to be studied.
When the SSA and antimicrobial agent were supplied to the E.
coli as a co-formulation (a–e), with all co-formulations apart
from co-formulation e there is an antagonistic effect, where
bacterial growth is decreased when compared to the additive
effects of the single SSA or antimicrobial agent alone. However,
























































































View Article Onlineagonistic effect. This is hypothesised to be because co-
formulation e retains similar properties to that of the SSA
alone at comparative concentrations. As we have previously
shown a decrease in CMC value of an SSA was found to correlate
with theMIC50 value obtained for a series of 50 SSAs against this
same strain of bacteria, where the CMC value is ca. $11 mM.15
Here the presence of cisplatin (6), supplied in a 1 : 1 ratio with
SSA 1 was shown to lower the CMC from 10.39 mM to 3.29 mM,
which we suggest could increase SSA antimicrobial activity in
line with these previous observations. Additionally, the size and
stability of those self-associated structures produced in the
presence of cisplatin (6) also retain some similarity (Table 4).
The presence of an SSA was not found to increase the efficacy
of isoniazid, either when supplied as the neutral compound (2),
or as the hydrochloric acid salt (3), with the exception of pre-
incubation of the hydrochloric acid salt with the bacteria.
However, this increase in efficacy is very small. The greatest
increase in antimicrobial efficacy was observed for 1 with
cisplatin (6). Here an enhancement of 34.6%, 12.3% and 11.4%
in bacterial growth inhibition was observed with prior incuba-
tion of the bacteria with SSA (1), prior incubation of the bacteria
with cisplatin (6) and the SSA co-formulated with the cisplatin
before addition, respectively (Fig. 4). Thus, the greatest
enhancement in antimicrobial efficacy was observed when the
cells were incubated with the SSA, prior to the addition of the
cisplatin (6).
Additionally, SSA 1 was also conrmed to slightly enhance
the efficacy of both ampicillin (5) and octenidine (4), which
impart antimicrobial effects through disruption of either the
cell wall (ampicillin) or cell membrane (octenidine). However,
these enhancement effects were only observed when the two
agents were supplied to the cells as a combination therapy (one
aer another) and not when added simultaneously as a co-
formulation. From evidence collected from our physicochem-
ical analysis we hypothesise that this is because these antimi-
crobial agents interfere with SSA self-association, as observed
within the scope of our 1H NMR dilution study experiments
(Fig. 3b and c). In disrupting SSA self-association and
membrane interaction events, we believe that this decreases the
proportion of therapeutic agents to arrive at the surface of the
cell in an active form, due to competitive multicomponent
interactions between antimicrobial/therapeutic agents at the
cell surface.Conclusions
As one of the greatest threats to human health remains the rise
of antimicrobial resistant bacterial infections, particularly those
caused by Gram-negative bacteria,37 new technologies are
required to combat this threat. Here, we have shown that the
self-associated aggregates formed by SSA 1 are capable of
interacting with antimicrobial/therapeutic agents currently in
use. However, of particular interest are the observed differences
in SSA/antimicrobial combination therapy over co-formulation
efficacy brought about by changing the order of agent addi-
tion to bacteria.© 2021 The Author(s). Published by the Royal Society of ChemistryHere, we have conrmed that 1 is able to increase the efficacy
of cisplatin (6) (a DNA chelating agent), ampicillin (5) (an
antibiotic that disrupts cell wall synthesis) and octenidine (4) (a
membrane disrupting antiseptic). However, in the case of 4 and
5 an antagonistic effect was observed when these agents were
added as a co-formulation. The summation of the evidence
presented here in leads us to conclude that SSA 1 acts most
effectively as an antimicrobial efficacy enhancer when supplied
as a combination therapy, through a prior 10minute incubation
period, before the addition of the antimicrobial/therapeutic
agent. We also hypothesise, through data provided from
a range of complimentary SSA co-formulation physicochemical
studies, that the degree of antimicrobial effect maybe due to
a combination of either destructive or constructive molecular
interaction events at the cell surface.Conflicts of interest
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